LAB Q3 2021 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$370M

Q3 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$29M-28.5% YoY

Gross Profit

$14M48.0% margin

Operating Income

-$20M-68.8% margin

Net Income

-$14M-48.6% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-8.1%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$11M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$282M

Total Liabilities

$183M

Stockholders' Equity

$99M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$40M	-28.5%
Gross Profit	$14M	$25M	-46.0%
Operating Income	-$20M	-$5M	-258.9%
Net Income	-$14M	-$6M	-130.8%

Revenue Segments

Product

$22M43%

Consumables

$12M23%

Instruments

$10M20%

Service

$6M12%

Grant

$461,0001%

Product and Service, Other

$461,0001%

Collaboration Revenue

$90,0000%

Geographic Segments

Americas

$13M46%

EMEA

$10M35%

Asia Pacific

$5M19%